Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.36 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4546652 | 0.89 | L3MBTL3 (0.46) | L3MBTL3MEN1KMT2AALDH1A1NPY5R | |
| SCHEMBL12414290 | 0.89 | L3MBTL3 (0.46) | L3MBTL3MEN1KMT2AALDH1A1NPY5R | |
| SCHEMBL12414289 | 0.89 | L3MBTL3 (0.46) | L3MBTL3MEN1KMT2AALDH1A1NPY5R | |
| SCHEMBL25110870 | 0.85 | NPY5R (0.45) | L3MBTL3MEN1KMT2AALDH1A1NPY5R | |
| SCHEMBL10160258 | 0.85 | L3MBTL3 (0.50) | L3MBTL3MEN1KMT2AALDH1A1NPY5R | |
| SCHEMBL19502759 | 0.85 | L3MBTL3 (0.50) | L3MBTL3MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL15045182 | 0.85 | L3MBTL3 (0.50) | L3MBTL3MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL23502255 | 0.82 | NPY5R (0.41) | L3MBTL3MEN1KMT2AALDH1A1NPY5R | |
| SCHEMBL19982000 | 0.82 | L3MBTL3 (0.47) | L3MBTL3MEN1KMT2AALDH1A1 | |
| SCHEMBL19659043 | 0.82 | NPY5R (0.41) | L3MBTL3MEN1KMT2AALDH1A1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-06-15 | — | — | US | disclosed |
| WO-2023083282-A1 | FUSED RING COMPOUND AS HPK1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. | 2021-03-25 | — | — | US | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-8563540-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8440651-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | L3MBTL3 3433/4885MEN1 4127/4885KMT2A 4144/4885 |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | ATF1, MAP3K1, ROCK1 | L3MBTL3 2418/4885MEN1 2899/4885KMT2A 2818/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | L3MBTL3 518/4885MEN1 1959/4885KMT2A 1422/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | L3MBTL3 3834/4885MEN1 3090/4885KMT2A 3548/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | L3MBTL3 3834/4885MEN1 3090/4885KMT2A 3548/4885 |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | L3MBTL3 813/4885MEN1 3076/4885KMT2A 890/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | L3MBTL3 3834/4885MEN1 3090/4885KMT2A 3548/4885 |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | MKI67, CCNC, CCNI | L3MBTL3 805/4885MEN1 534/4885KMT2A 877/4885 |
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | LRRK2, FABP7, PARK7 | L3MBTL3 1291/4885MEN1 1639/4885KMT2A 2689/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | L3MBTL3 4206/4885MEN1 4543/4885KMT2A 4343/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | L3MBTL3 4069/4885MEN1 1364/4885KMT2A 165/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | L3MBTL3 3433/4885MEN1 4127/4885KMT2A 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.